作　　者： (赵长阔）; (王先恒）; (曹颖）; (徐浪）; (袁智）;

机构地区： 遵义医学院,遵义563000

出　　处： 《中国新药杂志》 2017年第17期2003-2007,共5页

摘　　要： 度鲁特韦是目前最热门的抗艾滋病药物,为整合酶抑制剂,于2013年8月被FDA批准上市,可明显改善患者病情,目前尚未进入中国市场。详细了解该药的专利申报趋势,并深入分析专利整体布局以及技术脉络,可为我国企业对该药的仿制、"me-too"类及"me-better"类创新药提供相关信息储备以及借鉴。 Dolutegravir is currently the most popular anti-AIDS drug as an integrase inhibitor,which has been approved by US FDA in August,2013,while still not enter Chinese market. Dolutegravir can significantly improve the patient＇s condition. A detailed understanding of the drug patent declaration trends,and in-depth analysis of the overall layout of the patent and technical context,can provide relevant information and references for our generic and innovative drug companies,on the development of generic drug of dolutegravir and ＂me-too ＂and＂me-better＂innovative drugs.

关 键 词： 度鲁特韦 抗艾滋病 专利布局 仿制药 创新药